Clinical Application of Decellularized and Lyophilized Human Amnion/Chorion Membrane Grafts for Closing Post-Laryngectomy Pharyngocutaneous Fistulas

ZURAB KAKABADZE, MD, PhD,1,2∗ KONSTANTINE MARDALEISHVILI, MD, PhD,1,2
GEORGE LOLADZE, MD,2 IVANE JAVAKISHIVILI, MD,2 KONSTANTINE CHAKHUNASVILI, MD,1
LIKA KARALASHVILI, MD,1,3 NATIA SUKHITASHVILI, MD,3 GOCHA CHUTKERASHVILI, MD,3
ANN KAKABADZE, MD,1,3 AND DAVID CHAKHUNASVILI, MD, PhD3
1Tbilisi State Medical University, Tbilisi, Georgia
2Cancer Research Center, Tbilisi, Georgia
3Ilia State University, Tbilisi, Georgia

Background and Objectives: Squamous cell carcinoma is the most common pathological type among the cancers of the larynx. Standard treatment for squamous cell carcinoma of the larynx is the combination of chemotherapy, radiotherapy, and laryngectomy. Pharyngocutaneous fistula is a common complication of laryngectomy. We hypothesized that decellularized and lyophilized human amnion/chorion membrane can be an effective, non-invasive method of treating pharyngocutaneous fistula.

Methods: A total of 67 patients with laryngeal squamous cell carcinoma were retrospectively analyzed after treatment in a prospective trial. After preoperative chemotherapy, radiotherapy, and total or extended laryngectomy, primary wound healing occurred in 42 (62.7%) patients. Pharyngocutaneous fistula developed in 8 (11.9%) patients. Decellularized and lyophilized human amnion/chorion membrane grafts were used to reconstruct the fistulas.

Results: The average time for the full healing of the wound in all patients after transplantation of these grafts was 18 days.

Conclusion: The advantages of using these grafts over other existing methods of pharyngocutaneous fistula treatment are that they are non-invasive, prevent donor morbidity, and enable management of the wound without using classical wound gauze.

J. Surg. Oncol. 2016;113:538–543. © 2016 The Authors. Journal of Surgical Oncology Published by Wiley Periodicals, Inc.

Key Words: decellularized human amniotic membrane; pharyngocutaneous fistula; squamous cell carcinoma; total laryngectomy

INTRODUCTION

Treatment of laryngeal cancer is complex, and an ideal strategy has not yet been developed. Worldwide, 157,000 new cases of laryngeal cancer were diagnosed in 2012 [1], and according to the United States National Cancer Institute, the incidence of new cases of larynx cancer was 3.2 per 100,000 men and women [2]. Squamous cell carcinoma is the most common cell type among the cancers of the larynx [3–5]. Unfortunately, 40% of patients have late presentations (Stage III or IV) of disease [6,7]. Tumors may be identified in earlier stages, when vocal cords are affected by tumor. But, in most of the cases, tumors develop above or below vocal cords, which results in tumors manifesting at a later stage, as they remain asymptomatic for a longer period of time. In those cases, wide field resections are necessary, including total or extended laryngectomy, with possible resection of the base of tongue, and reconstruction with pharyngostomy, esophageal, or tracheal stomas [8,9].

Early complications of total laryngectomy include wound hematoma and/or infection, along with tracheoesophageal, pharyngotratcahal, or pharyngocutaneous fistulas [10–13]. Pharyngocutaneous fistula (PCF) is the most frequent major complication of those mentioned above. Rates of PCF between 8.5% and 24% have been most frequently reported [14–23]. Factors associated with the occurrence of PCF are stage of cancer, extent of resection, the use of preoperative radiation treatment in doses at or exceeding 50 Gy, and the method of repair of the pharyngeal defect [12,24]. A variety of treatments for PCF have been used, including local or regional flaps. Unfortunately, complications rates for these treatments remain high, in part due to impaired wound healing in the face of preoperative radiation treatment [25–36].

Attention has recently been focused on biological and biosynthetic materials, hydrogel membranes, and three-dimensional scaffolds, which have been successfully used for treatment of non-healing wounds of various etiologies [37–42]. Human amniotic membrane has aroused particular interest in treatment of non-healing wounds, as it possesses immunomodulative, anti-microbial, anti-inflammatory, fibrogenetic, and angiogenetic properties, as well as increasing extracellular matrix deposition [43–52].

The hypothesis for this study was that decellularized and lyophilized human amnion/chorion membrane (DLHACM) grafts could be an effective and non-invasive treatment for PCF after total laryngectomy, obviating the need for further surgical procedures. The aim of the study

Grant sponsor: Cancer Research Center, Tbilisi, Georgia.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Conflict of interest: The terms of this arrangement have been reviewed and approved by all institutions involved in accordance with their policy on objectivity in research.
*Correspondence to: Zurab Kakabadze, MD, PhD, Tbilisi State Medical University, 33 Vaja Pshavela Avenue, 0177 Tbilisi, Georgia. E-mail: zurab.kakabadze@gmail.com

Received 7 October 2015; Accepted 28 December 2015
DOI 10.1002/jso.24163
Published online 21 January 2016 in Wiley Online Library (wileyonlinelibrary.com).

© 2016 The Authors. Journal of Surgical Oncology Published by Wiley Periodicals, Inc.
Clinical Application of Human Amniotic Graft

Methods

All patients signed written informed consent for the study, conducted according to guidelines of the 1975 Declaration of Helsinki, and approved by the Ethics Committee of the Georgian National Institute of Medical Research in Tbilisi, Georgia.

Fabrication of DLHACM Grafts

Three placentas were obtained from donors who signed an informed consent form and who gave birth at 38–42 weeks of gestation. All donors had normal pregnancies and delivered healthy newborn babies with weights ranging from 2,300 to 3,900 grams.

Decellularization of placenta was performed according to our previously described method [53]. Briefly, newly acquired placentas were washed with 0.9% saline solution and heparin at 37°C under physiological pressure. For this purpose, polyethylene catheters were inserted into the umbilical artery and vein of the placentas and fixed in place with sutures. The placentas were flushed through the arterial catheter until clear solution was returned through the umbilical vein. After the washing, placentas were frozen at −80°C. Frozen placentas were then thawed to 40°C and washed with Phosphate Buffered Saline (PBS Sigma) overnight, perfusing PBS through the catheter in the placental artery. Placentas were then perfused with Sodium Dodecyl Sulfate (SDS, Sigma) in distilled water for 72 hr starting with 0.01% SDS for 24 hr, then with 0.1% SDS for 24 hr, and finally with 1% SDS for 24 hr. Subsequently, to remove residual SDS, placentas were washed with distilled water for 15 min and with 1% Triton X-100 (Sigma) for 30 min. Decellularized placentas were then washed with PBS for 1 hr.

After the decellularization process, amniotic membranes were separated from the placenta and cut into 14 × 1 cm flaps, and fixed on special glass frames. The amniotic membranes were then lyophilized using Power Dry PL 6,000 Freeze Dryers. After lyophilization, the DLHACM grafts were packed in a disposable plastic bag and sterilized with gamma radiation using a dose of 15 kGy. The DLHACM grafts were then stored aseptically at room temperature until use.

DNA Quantification of DLHACM Grafts

DNA was isolated from the grafts with standard methods using a commercial extraction kit (G-spin Kit; iNTRON Biotechnology). The total DNA was determined on a spectrophotometer (NanoDrop 1000; Thermo Fisher Scientific) at a wavelength of 260 nm. All samples were normalized to the human amnion dry weight.

The DNA content of human amnion/chorion membrane before treatment was 338 μg/ml. After the decellularization and lyophilization procedure, residual DNA content was less than 2%.

Histology and Fluorescence Immunohistochemistry

Histologic evaluation of human amniotic membranes was done both before and after decellularization and lyophilization. Cryosections (5 mm thick) were routinely processed and examined by light microscopy after H&E and Masson’s trichrome staining.

Fluorescence immunohistochemistry was done according to the following methods. To test the Collagen Iα1 and Fibronectin antibodies on DLHACM, formalin-fixed paraffin embedded tissue sections 5 um thick were cut on a rotary microtome, mounted on charged slides, and baked overnight at 50°C in an oven. All staining procedures were performed at a room temperature. The slides were deparaffinized and rehydrated with water. Antigen retrieval was performed using steam and proteinase K digestion methods. After antigen retrieval, the slides were allowed to cool at room temperature for 20 min prior to the next step. Then the slides were rinsed in three PBS cycles for 5 min each and were blocked with 3% H₂O₂. After rinsing in three PBS cycles, the slides were incubated in primary antibody consisting of Collagen Iα1 (sc-25974 at 1:100) and Fibronectin (sc-8422 at 1:200) diluted with iHC-Tek Antibody Diluent for 1 hr at room temperature. The slides were then washed three times in PBS and incubated with biotinylated secondary antibody for 30 min. The slides were washed in PBS and then incubated with HRP-Streptavidin for 30 min. Afterwards, incubation with DAB chromagen substrate solution was performed for 5–10 min, and then slides were rinsed with PBS and counterstained with Mayer’s hematoxylin. The stained slides were examined with regular microscope.

The current histological and immunohistochemical studies demonstrated the five different layers of the normal human amniotic membrane: epithelium; basement membrane; compact layer; fibroblast layer; and intermediate or sponge layer. The basement layer was formed by type III and IV collagens and glycoproteins such as laminin, fibronectin, and nidogen, which are the products of secretion of the epithelial layer cells of the amnion [54,55]. Next was the compact layer, forming the main fiber structure of the amnion, which was represented by types I, III, IV, and V collagen and fibronectin (Fig. 1).

Scanning Electron Microscopy (SEM) of DLHACM Grafts

The DLHACM grafts were dehydrated by processing with ethanol solution and were then dried with a Toussimis Samdri-780 critical point dryer (Toussimis Research Corporation, Rockville, MD). After drying, all tissues were sputter coated lightly with gold (adjustments are shown below) and imaged on a Hitachi Scanning Electron microscope. Scanning electron micrographs at low magnification demonstrated that types I and III collagen were bundled in the compact layer, and types IV and V collagens were located between the compact layer and basement membrane. These findings confirmed other studies, demonstrating that the process of decellularization and lyophilization used here preserved the unique, and porous structure of human amnion/chorion membrane within the DLHACM grafts [56–58].

Gene Expression Analysis of Human Amnion/Chorion Membrane and DLHACM Grafts

Total RNA from the amnion tissue was purified using miRNAesy mini kit according to the manufacturer’s instructions (Qiagen). The cDNA was synthesized using the iScript cDNA Synthesis Kit (BioRad). Q-PCR was carried out with iTaq universal SYBR green supermix (BioRad) on a 7,500 Fast Real-Time PCR system (Life Technologies). The 18S rRNA was used as internal control for gene expression normalization.

These studies demonstrated that the DLHACM grafts consisted of a large number of different growth factors, especially BMP7, BMP8a, which enhance the wound healing process (Fig. 2).

RESULTS

A total of 65 male and two female patients (mean age 54 years) with laryngeal squamous cell carcinoma, undergoing surgical treatment from January 2009 to December 2014 in Cancer Research Center of Tbilisi, Georgia, were enrolled into the study. All patients received comprehensive treatment consisting of preoperative chemotherapy and 50 Gy radiotherapy, followed by laryngectomy. Of the 67 patients, 12 (17.9%) were Stage I/II, 34 (50.7%) were Stage III, and 21 (31.4%) were Stage IV. Ten (14.9%) patients had total laryngectomy, 49 (73.1%) had total laryngectomy plus neck dissection, and 8 (12.0%) had extended laryngectomy and neck dissection. In all cases, the initial defects after laryngectomy were closed using local and/or regional (deltoplectoral or thoraco-dorsal) flaps.
Primary wound healing occurred in 42 (62.7%) patients. The remaining 25 (37.3%) patients developed wound complications including hematoma, wound separation, necrosis of the skin edges, and flap necrosis. PCF occurred in various locations of the neck area in 8 (11.9%) patients, and DLHACM grafts were used to close these fistulas.

**Application of DLHACM Grafts to Treat PCF**

For all eight patients who developed a PCF, the wound was prepared with solution of 10% polyvidone-iodine. After anaesthesia was induced with 1% lidocaine without epinephrine, necrotic tissue was mechanically debrided until viable, and bleeding tissue were encountered. DLHACM was delicately applied to the region, so that there were no air bubbles or blood clots between DLHACM and host tissue. DLHACM was generally tightly fixed to the wound, and only rarely were surgical sutures or fibrin glue applied.

The stages of reconstruction of a large PCF in the submental space are shown in Figure 3. All eight PCF closed, and the average time for the full healing of the wound after using DLHACM grafts was 18 days. Patients were followed every 3 months after closure of PCF, and there have not been any recurrences of PCF.

*Journal of Surgical Oncology*
DISCUSSION

Historically, the treatment of PCF after total laryngectomy has employed local or regional flaps created from the skin, muscles, and mucous membrane [25–29]. Local flaps may be unreliable, since in most cases they have been affected by irradiation [30–32]. The use of local flaps can lead to recurrence rates for PCF as high as 66.6%, necessitating closure using pectoralis major myocutaneous flaps [33]. Even after primary reconstruction of PCF with pectoralis major myocutaneous flaps, the development of recurrent PCF varies between 16% and 19%. The operation can also be accompanied by donor site infection (18%), donor site hematoma (10%), and flap necrosis (10%), with overall wound complications rates as high as 60% [34–36]. These complications occur on the backdrop of operating in a radiated, contaminated space with significant tumors burdens, all of which further complicate wound healing [59–61].

The healing of postoperative PCF after using the DLHACM grafts was possible due to the unique characteristics of the human amnion/chorion membrane, which possesses immunomodulative, anti-microbial, and anti-inflammatory properties, hastens fibrogenesis and angiogenesis, and increases extracellular matrix deposition [62–65]. The amniotic membrane, separated from the chorion by the intermediate or the sponge layer, is mostly composed of type III collagen and glycoproteins. It also contains numerous growth factors, such as EGF, bFGF, KGF, VEGF, TGF-a, TGF-b, PDGF, HGF, and NGF [66–71]. In this study, the DLHACM grafts were tightly attached to the wound surface and efficiently absorbed wound exudates. It has also been previously demonstrated that this tight adherence allows removal of surface debris and bacteria from the wound [72]. The unique physicomemchnical and compositional properties of the human amnion/chorion membrane promote the migration of keratinocytes and various epithelial cells. Angiogenic growth factors, which are components of DLHACM grafts, also probably contribute to significant acceleration of neovascularization and formation of granulation tissue. DLHACM grafts also form an early closed physiologic space with the host, forming an adherence barrier with the wound via fibrin and elastin linkages that close the wound and prevent contamination [73].

Fig. 2. Relative gene expression levels in native human amnion membrane and decellularized and lyophilized human amnion/chorion membrane.

Fig. 3. Application of decellularized and lyophilized human amnion/chorion membrane graft on the pharyngocutaneous fistula. (A) Pharyngocutaneous fistula developed after extended laryngectomy in submental region before transplantation; (B and C) After transplantation of decellularized and lyophilized human amnion/chorion membrane; (D) healing process on day 14.

Journal of Surgical Oncology
CONCLUSION

After laryngectomy, the occurrence of a PCF is a severe complication. DLHACM grafts are very good biomaterials for clinical application, especially in patients suffering from this complication. The advantages of using DLHACM grafts over other existing treatment methods for PC is that they are non-invasive, prevent donor morbidity, and are effective in closing PCF without further surgical intervention.

REFERENCES

1. Cancer research UK, http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/laryngeal-cancer#heading-Zero, Sept 2015.
2. SEER cancer statistics factsheet: Larynx cancer. National cancer institute. Bethesda, MD, http://seer.cancer.gov/statfacts/html/laryn.html.
3. Sirikanjanapong S, Lanson B, Amin M, et al.: Collision tumor of primary laryngeal mucosal melanoma and invasive squamous cell carcinoma with IL-17A and CD70 gene over-expression. Head Neck Pathol 2010;4:295–299.
4. Manur S, Forastiere AA: Head and neck cancer: Changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 2008;83:489–501.
5. Barnes L: Surgical pathology of the head and neck, 3rd edition. Lippincott Williams & Wilkins; 2001.
6. Mohamed TE Tabbakh, Mohamed Ahmed Ahmed, Doaa F Sedik, et al.: Management of patients with cancer of the larynx in Suez Canal University Teaching Hospital: 5 years’ experience. Egypt J Otolaryngol 2014:30:30–33.
7. Janfaza P, Nadol J, Galli R: Surgical anatomy of the head and neck [chapter 11]. Anatomy of the neck. Philadelphia: Lippincott Williams & Wilkins; 2001.
8. D’Cruz AK, Sharma S, Pai PS: Current status of near-total laryngectomy: Review. J Laryngol Otol 2012;126:556–562.
9. Forastiere AA, Weber RS, Troatti A: Organ preservation for advanced larynx cancer: Issues and outcomes. J Clin Oncol 2015. Pii: JCO. 2015.61.2978.
10. Aslam MJ, Ahmed Z, Aslam MA, et al.: Complication of total laryngectomy. Pak J Med Sci 2006;22:33–37.
11. Dedivitis RA, Valea M, et al.: Fistula following total laryngectomy. Otolaryngol Pol 2007;61:271–279.
12. Dedivitis RA, Ribeiro KC, Castro MA, et al.: Pharyngocutaneous fistula—a continuing clinical problem. Otolaryngol Pol 2007;61:277–281.
13. Sifrer R, Strojan P: Pectoralis major myocutaneous flap of the donor arm—a novel technique for the reduction of donor site morbidity in radial forearm free flap. Head Neck 2015.
14. El-Marakby HH: The reliability of pectoralis major myocutaneous flap following total laryngectomy. Acta Otorhinolaryngol Ital 2007;27:2–5.
15. Virtaniemi JA, Kumpulainen EJ, Hirvikoski PP, et al.: The incidence and etiology of postlaryngectomy pharyngocutaneous fistulae. Head Neck 2001;23:29–33.
16. Anis N, Nikakhlagh S, Kazemi M: Pharyngocutaneous fistula after total laryngectomy. Ann Plast Surg 2002;112:990–996.
17. Redaelli de Zinis LO, Ferrari L, Tomenzioli D, et al.: Postlaryngectomy pharyngocutaneous fistula: Incidence, predisposing factors, and therapy. Head Neck 1999;21:131–138.
18. Venegas MP, Leon X, Quer M, et al.: Complications of total laryngectomy in relation to the previous radiotherapy. Acta Otorrinolaringol Esp 1997;48:639–646.
19. Shemen LJ, Spiro RH: Complications following laryngectomy. Head Neck Surg 1986;8:185–191.
20. Kasapoglu F, Eriksen L, Coskun H, et al.: The management of pharyngocutaneous fistulas after total laryngectomy and the factors affecting their incidence. Kulak Burun Bogaz Ihtis Derg 2005;11:5–10.
21. Betlejewski S, Szymańska-Skrzypek A: Post-laryngectomy pharyngocutaneous fistula—contemporary clinical problem. Otolaryngol Pol 2007;61:271–279.
22. Paul M, Kaur P, Herson M, et al.: Use of clotted human plasma and aprotinin in skin tissue engineering: A novel approach to engineering composite skin on a porous scaffold. Tissue Eng Part C Methods 2015;21:1098–1104.
23. MacLeod TM, Cambrey A, Williams G, et al.: Evaluation of permacol as a cultured skin equivalent. Burns 2008;34:1169–1175.
24. Han J, Dong Y, Su Z, et al.: Preparation, characteristics and assessment of a novel gelatin-chitosan sponge scaffold as skin tissue engineering material. Int J Pharm 2014;476:124–133.
25. Wei JP, Zhang TS, Kawa S, et al.: The Human amnionisolated cells tissue engineering material. Int. J Pharm 2014;476:124–133.
26. Dhillon M, Carter CP, Morrison J, et al.: Comparison of skin graft success in the head & neck with and without the use of a pressure dressing. J Maxillofac Oral Surg 2015;14:240–242.
27. Achauer BM, VanderKam VM, Celliok B, et al.: Augmentation of facial soft-tissue defects with AlloDerm dermal graft. Am J Surg 1998;167:91–95.
44. Weiss ML, Anderson C, Medicetty S, et al.: Immune response of human umbilical wharton jelly-derived cell. Stem Cells 2008; 26:2865–2874.
45. Talmi VP, Sigler L, Inge E, et al.: Antibacterial properties of human amniotic membranes. Placenta 1991;12:285–288.
46. Colocho G, Graham WP, 3rd, Greene AE, et al.: Human amniotic membrane as a physiologic wound dressing. Arch Surg 1974;109:370–373.
47. Rauz S, Saw VP: Serum eye drops, amniotic membrane and limbal epithelial stem cells–tools in the treatment of ocular surface disease. Cell Tissue Bank 2010;11:13–27.
48. Wichayacoop T, Briksawan P, Tuntivanich P, et al.: Anti-inflammatory effects of topical supernatant from human amniotic membrane cell culture on canine deep corneal ulcer after human amniotic membrane transplantation. Vet Ophthalmol 2009;12:28–35.
49. Yazdanpanah G, Paeini-Vayghan G, Asadi S, et al.: The effects of cryopreservation on angiogenesis modulation activity of human amniotic membrane. Cryobiology 2015. Pii: S0011-2240(15)00250-3.
50. Rodriguez-Ares MT, López-Valladares MJ, Tourino R, et al.: Effects of lyophilization on human amniotic membrane. Acta Ophthalmol 2009;87:396–403.
51. Bowler PG, Duerrden BI, Armstrong DG: Wound microbiology and associated approaches to wound management. Clin Microbiol Rev 2001;14:244–269.
52. Velding K, Klis SA, Abass KM, et al.: Wound care in Buruli ulcer disease in Ghana and Benin. Am J Trop Med Hyg 2014;91:313–318.
53. Karalashvili L, Kakabadze A, Vyshnevska G, et al.: Acellular human amniotic membrane as a three-dimensional scaffold for the treatment of mucogingival defects. Georgian Med News 2015;244-245:84–89.
54. Peng Y, Xuan M, Zou J, et al.: Freeze-dried rat bone marrow mesenchymal stem cell paracrine factors: A simplified novel material for skin wound therapy. Tissue Eng Part A 2015; 21:1036–1046.
55. Choi JS, Kim JD, Yoon HS, et al.: Full-thickness skin wound healing using human placenta-derived extracellular matrix containing bioactive molecules. Tissue Eng Part A 2013;19:329–339.
56. Parry S, Strauss JF: Premature rupture of the fetal membranes. New Engl J Med 1998;338:663–670.
57. Koob TJ, Lim JJ, Massee M, et al.: Properties of dehydrated human amnion/chorion composite grafts: Implications for wound repair and soft tissue regeneration. J Biomed Mater Res B Appl Biomater 2014;102:1353–1362.
58. Malak TM, Ockleford CD, Bell SC, et al.: Confocal immunofluorescence localization of collagen types I, III, IV, V and VI and their ultrastructural organization in term human fetal membranes. Placenta 1993;14:385–406.
59. Fraioli R, Johnson JT: Prevention and treatment of postsurgical head and neck infections. Curr Infect Dis Rep 2004;6:172–180.
60. González-Márquez R, Rodrigo JP, Suárez Nieto C: Prognostic significance of postoperative wound infections after total laryngectomy. Head Neck 2012;34:1023–1027.
61. Penel N, Fournier C, Roussel-Delvallez M, et al.: Prognostic significance of wound infections following major head and neck cancer surgery: An open non-comparative prospective study. Support Care Cancer 2004;12:634–639.
62. Niknejad H, Peirovi H, Jorjani M, et al.: Properties of the amniotic membrane for potential use in tissue engineering. Eur Cell Mater 2008;15:88–99.
63. Choi JS, Kim JD, Yoon HS, et al.: Full-thickness skin wound healing using human placenta-derived extracellular matrix containing bioactive molecules. Tissue Eng Part A 2013;19:329–339.
64. Guo Q, Lu X, Xue Y, et al.: A new candidate substrate for cell-matrix adhesion study: The acellular human amniotic matrix. J Biomed Biotechnol 2012;2012:306083.
65. Gruss JS, Jirsch DW: Human amniotic membrane: A versatile dressing. Can Med Assoc J 1978;118:1237–1246.
66. Lopez-Valladares MJ, Rodriguez-Ares MT, Tourino R, et al.: Donor age and gestational age influence on growth factor levels in human amniotic membrane. Acta Ophthalmol 2010;88:e211–e216.
67. Russo A, Bonci P, Bonci P: The effects of different preservation processes on the total protein and growth factor content in a new biological product developed from human amniotic membrane. Cell Tissue Bank 2012;13:353–361.
68. Kay H, Nelson D, Wang Y: “The placenta: From development to disease.” Wiley-Blackwell 2011.
69. Koob TJ, Lim JJ, Massee M, et al.: Angiogenic properties of dehydrated human amnion/chorion allografts: Therapeutic potential for soft tissue repair and regeneration. Vasc Cell 2014;6:10.
70. Massee M, Chinn K, Lei J, et al.: Dehydrated human amnion/chorion membrane regulates stem cell activity in vitro. J Biomed Mater Res B Appl Biomater 2015.
71. Alcaraz A, Mrowiec A, Insausti CL, et al.: Acellular device modifies the genetic program induced by TGFβ, stimulating keratinocyte proliferation and migration in chronic wounds. PLoS ONE 2015;18:e0135324.
72. Rao TV, Chandrasekhram V: Use of dry human and bovine amnion as a biological dressing. Arch Surg 1981;116:891–896.